Deal of the Week: J&J Nears Actelion Takeover Despite Twists and Turns

 Neither Bloomberg's M&A executive editor Jeff McCracken nor host Alex Sherman can remember a deal quite like Johnson & Johnson's pursuit of Swiss drugmaker Actelion. First J&J publicly stated it was in talks with Actelion. Then, J&J said talks were over, and another party (Sanofi) had entered talks to buy Actelion. But just a week later, J&J and Actelion announced they'd re-entered talks. Now Bloomberg reports the sides have reached a tentative agreement on price, and a deal may be announced before the end of the month. McCracken explains why Actelion is such a coveted asset and what other large health care deals may emerge in 2017.



    Before it's here, it's on the Bloomberg Terminal.